Shionogi & Co., Ltd. (Headquartered in Osaka, Japan; CEO: Isao Teshirogi, Ph.D.; hereafter referred to as “Shionogi”) has announced revisions to its dividend forecasts for the fiscal year ending March…
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a prominent global oncology firm, has unveiled its 2023 Responsible Business & Sustainability Report, spotlighting the company’s strategic direction, progress towards existing…
Bayer Group’s divisions demonstrated resilience and strength in several core areas, surpassing industry peers, according to CEO Bill Anderson during the virtual Annual Stockholders’ Meeting. Anderson praised the progress in…
Moderna, Inc. (NASDAQ: MRNA) has unveiled plans to share insights from its extensive respiratory portfolio, encompassing vaccines and vaccine candidates targeting COVID-19 (mRNA-1273, mRNA-1283), influenza (mRNA-1010, mRNA-1011/1012), and respiratory syncytial…
Biogen Inc. (Nasdaq: BIIB) has announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has given a favorable opinion for TOFIDENCE™…
Takeda has received a positive recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for the approval of fruquintinib, a selective inhibitor of vascular endothelial…
Merck, a prominent science and technology company, convened its 29th Annual General Meeting virtually today. With a significant majority, shareholders approved all items on the agenda, including the proposed dividend…
Vertex Pharmaceuticals (Nasdaq: VRTX) has received approval from the European Commission for the expansion of KALYDECO® (ivacaftor) labeling. This approval allows for the treatment of infants as young as 1…
Today, Pfizer Inc. (NYSE: PFE) announced the approval of BEQVEZ™ (fidanacogene elaparvovec-dzkt) by the U.S. Food and Drug Administration (FDA) for the treatment of adults grappling with moderate to severe…
Amgen (NASDAQ:AMGN) has announced its forthcoming submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for teprotumumab. Teprotumumab, a fully human monoclonal antibody and targeted inhibitor…
The American Thoracic Society (ATS) International Conference, scheduled from May 17-22 in San Diego, will host the unveiling of twenty-five abstracts featuring both approved and investigational medicines from Sanofi. Among…
Bristol Myers Squibb (NYSE: BMY) has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the approval of Opdivo® (nivolumab)…